All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
The Multiple Myeloma Hub are pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Mohamad Mohty, Saint-Antoine Hospital and Sorbonne University, Paris, FR, discusses practice-changing abstracts in multiple myeloma presented at ASH 2019.
Prof. Mohty discusses important trials in patients with relapsed/refractory multiple myeloma such as the CAR T trials CARTITUDE-1 and LEGEND-2, studies involving bispecific antibodies such as CC-93269, and new monoclonal antibodies such as TAK-079. Whilst the bispecific antibodies may challenge the role of CAR T in myeloma, Prof. Mohty notes that we will likely need to use all these tools, in different patient populations. Next, Prof. Mohty discusses key trials in smoldering myeloma, especially in high-risk patients, such as GEM-CESAR, and concludes by talking about advances in frontline therapy presented at ASH such as the ALCYONE trial.
Practice-changing abstracts in multiple myeloma presented at ASH 2019
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox